Low back pain as the presenting sign in a patient with primary extradural melanoma of the thoracic spine - A metastatic disease 17 Years after complete surgical resection

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Katalinic, Darko ^a   Anic, Branimir ^a   Stern Padovan, Ranka ^a   Mayer, Miroslav ^a   Sentic, Mirna ^a   Cikes, Nada ^a   Zarkovic, Kamelija ^a   Dotlic, Snjezana ^a   Plestina, Stjepko ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Low back pain; Metastatic disease; Primary spinal melanoma

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; FERRITIN; HEMOGLOBIN; IRON; LACTATE DEHYDROGENASE; MELAN A; TAMOXIFEN; TECHNETIUM 99M;

ADULT; ANEMIA; ARTICLE; BONE BIOPSY; BONE SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CASE REPORT; DEATH; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEBRILE NEUTROPENIA; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPESTHESIA; IMMUNOHISTOCHEMISTRY; IRON BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LAMINECTOMY; LOW BACK PAIN; LYMPHADENOPATHY; MALE; MELANOMA; METASTASIS; METASTASIS INHIBITION; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE ORGAN FAILURE; MYELOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIMARY EXTRADURAL MELANOMA; PRIMARY TUMOR; SEPSIS; SPASTIC PARAPLEGIA; SPINE TUMOR; THORACIC SPINE; THORAX RADIOGRAPHY; THROMBOCYTOSIS; WEIGHT REDUCTION; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE COMPLICATION; SPINAL CORD TUMOR; THORAX TUMOR; VERTEBRA;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LOW BACK PAIN; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SPINAL NEOPLASMS; THORACIC NEOPLASMS; THORACIC VERTEBRAE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 81155138330     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-150     Document Type: Article

References (38)

1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002, 146:1-6.
2. Kounin GK, Romansky KV, Traykov LD, Shotekov PM, Stoilova DZ. Primary spinal melanoma with bilateral papilledema. Clin Neurol Neurosurg 2005, 107:525-527. 10.1016/j.clineuro.2004.10.013, 16202828.
3. Naing A, Messina JL, Vrionis FR, Daud AI. Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin Oncol 2004, 22:3194-3195. 10.1200/JCO.2004.09.021, 15284274.
4. Brat DJ, Giannini C, Scheithauer BW, Burger PC. Primary melanocytic neoplasms of the central nervous system. Am J Surg Pathol 1999, 23:745-754. 10.1097/00000478-199907000-00001, 10403296.
5. Hayward RD. Malignant melanoma and the central nervous system. J Neurol Neurosurg Psychiatry 1976, 39:526-530. 10.1136/jnnp.39.6.526, 492341, 950562.
6. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. J Clin Oncol 1999, 17:2745-2751.
7. Yamasaki T, Kikuchi H, Yamaschita J, Asato R, Fujita M. Primary spinal intramedullary malignant melanoma: case report. Neurosurgery 1989, 25:117-121. 10.1227/00006123-198907000-00023, 2755570.
8. Farrokh D, Fransen P, Faverly D. MR findings of a primary intramedullary malignant melanoma: case report and literature review. Am J Neuroradiol 2001, 22:1864-1866.
9. Larson TC, Houser OW, Onofrio BM, Peipgras DG. Primary spinal melanoma. J Neurosurg 1987, 66:47-49. 10.3171/jns.1987.66.1.0047, 3783259.
10. Isiklar I, Leeds NE, Fuller GN, Kumar AJ. Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content. Am J Roentgenol 1995, 165:1503-1512.
11. Woodruff WW, Djang WT, McLendon RE, Heinz ER, Voorhees DR. Intracerebral malignant melanoma: high-field-strength MR imaging. Radiology 1987, 165:209-213.
12. Fon GT, Wong WS, Gold RH, Kaiser LR. Skeletal metastases of melanoma: radiographic, scintigraphic, and clinical review. Am J Roentgenol 1981, 137:103-108.
13. Edelstyn GA, Gillespie PJ, Grebell ES. The radiologic demonstration of osseous metastases: experimental observations. Clin Radiol 1967, 18:158-164. 10.1016/S0009-9260(67)80010-2, 6023348.
14. Patten RM, Shuman WP, Teefey S. Metastases from malignant melanoma to the axial skeleton: a CT study of frequency and appearance. Am J Roentgenol 1990, 155:109-112.
15. Finger PT, Kurli M, Wesley P, Tena L, Kerr KR, Pavlick A. Whole body PET/CT imaging for detection of metastatic choroidal melanoma. Br J Ophthalmol 2004, 88:1095-1097. 10.1136/bjo.2003.039289, 1772278, 15258035.
16. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology 2009, 23:488-496. 2737459, 19544689.
17. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiot Oncol Biol Phys 1988, 15:859-864.
18. Herbert SH, Solin L, Rate WR, Schultz DJ, Hanks GE. The effect of palliative radiation therapy on epidural compression due to metastatic malignant melanoma. Cancer 1991, 67:2472-2476. 10.1002/1097-0142(19910515)67:10<2472::AID-CNCR2820671014>3.0.CO;2-V, 1707746.
19. Cooper JS. The evolution of the role of radiation therapy in the management of mucocutaneous malignant melanoma. Hematol Oncol Clin North Am 1998, 12:849-862. 10.1016/S0889-8588(05)70027-7, 9759583.
20. Geara FB, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am 1996, 76:1383-1398. 10.1016/S0039-6109(05)70521-1, 8977557.
21. Hamilton AJ, Lulu BA, Fosmire H, Stea B, Cassady JR. Preliminary clinical experience with linear accelerator-based spinal stereotactic radiosurgery. Neurosurgery 1995, 36:311-319. 10.1227/00006123-199502000-00010, 7731511.
22. Gerszten PC. The role of minimally invasive techniques in the management of spine tumors: percutaneous bone cement augmentation, radiosurgery, and microendoscopic approaches. Orthop Clin North Am 2007, 38:441-450. 10.1016/j.ocl.2007.03.004, 17629991.
23. Gerszten PC, Ozhasoglu C, Burton SA, Vogel WJ, Atkins BA, Kalnicki S, Welch WC. CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery 2004, 55:89-99.
24. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:1743-1751.
25. Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991, 9:1821-1830.
26. Flaherty LE, Robinson W, Redman BG, Gonzalez R, Martino S, Kraut M, Valdivieso M, Rudolph AR. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993, 71:3520-3525. 10.1002/1097-0142(19930601)71:11<3520::AID-CNCR2820711110>3.0.CO;2-A, 8490900.
27. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994, 12:1553-1560.
28. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999, 17:968-975.
29. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001, 11:75-81. 10.1097/00008390-200102000-00009, 11254118.
30. Wöll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999, 9:575-581. 10.1097/00008390-199912000-00006, 10661768.
31. O'Day SJ, Kim CJ, Reintgen DS. Metastatic Melanoma: Chemotherapy to Biochemotherapy. Cancer Control 2002, 9:31-38.
32. O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol 2009, 27:6207-6212. 10.1200/JCO.2008.20.3075, 19917850.
33. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003, 100:8372-8377. 10.1073/pnas.1533209100, 166236, 12826605.
34. Robert C, Thomas L, Bondarenko I, O'Day S, MD JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526. 10.1056/NEJMoa1104621, 21639810.
35. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-23. 10.1056/NEJMoa1003466, 20525992.
36. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, . BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 21639808, BRIM-3 Study Group.
37. Machet L, Perrinaud A, Giraudeau B. Routine ultrasonography in melanoma follow-up?. The Lancet Oncology 2005, 6:2.
38. DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer 2001, 91:1520-1524. 10.1002/1097-0142(20010415)91:8<1520::AID-CNCR1160>3.0.CO;2-6, 11301400.